ReviewTranslational respiratory medicine2014
The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update.
Review in Translational respiratory medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities.Pulmonary pharmacology & therapeutics · 2022Review
- Shared Decision-Making Facilitates Inhaler Choice in Patients with Newly-Diagnosed Chronic Obstructive Pulmonary Disease: A Multicenter Prospective Study.International journal of chronic obstructive pulmonary disease · 2022Article
- Depletion and Dysfunction of Dendritic Cells: Understanding SARS-CoV-2 Infection.Frontiers in immunology · 2022Review
- Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.Advanced drug delivery reviews · 2021Review
- Targeted Phage Display-based Pulmonary Vaccination in Mice and Non-human Primates.Med (New York, N.Y.) · 2021Article
- Invited review: human air-liquid-interface organotypic airway tissue models derived from primary tracheobronchial epithelial cells-overview and perspectives.In vitro cellular & developmental biology. Animal · 2021Review
- Preparation of Hybrid Alginate-Chitosan Aerogel as Potential Carriers for Pulmonary Drug Delivery.Polymers · 2020Article
- Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs.Neuropharmacology · 2020Review
- Interplay between SARS-CoV-2 and the type I interferon response.PLoS pathogens · 2020Review
- Pharmacokinetic Analysis of Epithelial/Endothelial Cell Barriers in Microfluidic Bilayer Devices with an Air-Liquid Interface.Micromachines · 2020Article
- Advanced in vitro lung-on-chip platforms for inhalation assays: From prospect to pipeline.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019Review
- MultiscaleCurrent opinion in biomedical engineering · 2019Article
- Capturing the Onset of Bacterial Pulmonary Infection in Acini-On-Chips.Advanced biosystems · 2019Article
- Aerosolized recombinant human butyrylcholinesterase delivered by a nebulizer provides long term protection against inhaled paraoxon in macaques.Chemico-biological interactions · 2019Article
- The effect of aerosolized indomethacin on lung inflammation and injury in a rat model of blunt chest traumaCanadian journal of surgery. Journal canadien de chirurgie · 2018Article
- One (sub-)acinus for all: Fate of inhaled aerosols in heterogeneous pulmonary acinar structures.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2018Review
- Regional Ventilation Is the Main Determinant of Alveolar Deposition of Coarse Particles in the Supine Healthy Human Lung During Tidal Breathing.Journal of aerosol medicine and pulmonary drug delivery · 2017Article
- Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavenger.Annals of the New York Academy of Sciences · 2016Review
- Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.Kona : powder science and technology in Japan · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until the late 1990s, aerosol therapy consisted of beta2-adrenergic agonists, anti-cholinergics, steroidal and non-steroidal agents, mucolytics and antibiotics that were used to treat patients with asthma, COPD and cystic fibrosis. Since then, inhalation therapy has matured to include drugs that: (1) are designed to treat diseases outside the lung and whose target is the systemic circulation (systemic drug delivery); (2) deliver nucleic acids that lead to permanent expression of a gene construct, or protein coding sequence, in a population of cells (gene therapy); and (3) provide needle-free immunization against disease (aerosolized vaccination). During the evolution of these advanced applications, it was also necessary to develop new devices that provided increased dosing efficiency and less loss during delivery. This review will present an update on the success of each of these new applications and their devices. The early promise of aerosolized systemic drug delivery and its outlook for future success will be highlighted. In addition, the challenges to aerosolized gene therapy and the need for appropriate gene vectors will be discussed. Finally, progress in the development of aerosolized vaccination will be presented. The continued expansion of the role of aerosol therapy in the future will depend on: (1) improving the bioavailability of systemically delivered drugs; (2) developing gene therapy vectors that can efficiently penetrate the mucus barrier and cell membrane, navigate the cell cytoplasm and efficiently transfer DNA material to the cell nucleus; (3) improving delivery of gene vectors and vaccines to infants; and (4) developing formulations that are safe for acute and chronic administrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.